Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 12, 2022

Association Between Immune-Related Adverse Events and Survival in Patients With Solid Tumors Treated With ICIs

Cancer Treatment Reviews


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Treatment Reviews
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Cancer Treat. Rev 2022 Nov 01;110(xx)102452, M Kfoury, M Najean, A Lappara, AL Voisin, S Champiat, JM Michot, S Laghouati, C Robert, B Besse, JC Soria, O Lambotte, C Massard, A Marabelle, M Texier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading